845.95 USD
-6.09 (-0.71%)
845.95 USD
0 (0%)
Overall ARGX gets a fundamental rating of 6 out of 10. We evaluated ARGX against 530 industry peers in the Biotechnology industry. ARGX has an excellent financial health rating, but there are some minor concerns on its profitability. ARGX is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make ARGX a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year ARGX was profitable.
In the past year ARGX had a positive cash flow from operations.
ARGX had negative earnings in 4 of the past 5 years.
ARGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ARGX's Return On Assets of 17.84% is amongst the best of the industry. ARGX outperforms 96.23% of its industry peers.
The Return On Equity of ARGX (21.00%) is better than 96.23% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.01%, ARGX belongs to the top of the industry, outperforming 91.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 6.01% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARGX has a better Profit Margin (41.97%) than 97.36% of its industry peers.
ARGX has a better Operating Margin (15.30%) than 93.21% of its industry peers.
ARGX has a better Gross Margin (89.40%) than 91.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ARGX is destroying value.
The number of shares outstanding for ARGX has been increased compared to 1 year ago.
The number of shares outstanding for ARGX has been increased compared to 5 years ago.
The debt/assets ratio for ARGX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 30.57 indicates that ARGX is not in any danger for bankruptcy at the moment.
ARGX's Altman-Z score of 30.57 is amongst the best of the industry. ARGX outperforms 93.40% of its industry peers.
The Debt to FCF ratio of ARGX is 0.14, which is an excellent value as it means it would take ARGX, only 0.14 years of fcf income to pay off all of its debts.
ARGX's Debt to FCF ratio of 0.14 is amongst the best of the industry. ARGX outperforms 95.47% of its industry peers.
ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, ARGX is in line with its industry, outperforming 45.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 30.57 |
ROIC/WACC0.81
WACC7.43%
2.3 Liquidity
ARGX has a Current Ratio of 5.60. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.60, ARGX is in line with its industry, outperforming 58.68% of the companies in the same industry.
ARGX has a Quick Ratio of 5.27. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 5.27, ARGX perfoms like the industry average, outperforming 59.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1512.50%, which is quite impressive.
ARGX shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.71%.
Measured over the past years, ARGX shows a very strong growth in Revenue. The Revenue has been growing by 94.61% on average per year.
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
Revenue 1Y (TTM)64.71%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
3.2 Future
ARGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 107.34% yearly.
The Revenue is expected to grow by 34.98% on average over the next years. This is a very strong growth
EPS Next Y939.88%
EPS Next 2Y310.28%
EPS Next 3Y177.32%
EPS Next 5Y107.34%
Revenue Next Year94.97%
Revenue Next 2Y63.05%
Revenue Next 3Y48.34%
Revenue Next 5Y34.98%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 63.08, which means the current valuation is very expensive for ARGX.
90.00% of the companies in the same industry are more expensive than ARGX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.50. ARGX is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 26.92, which means the current valuation is very expensive for ARGX.
92.64% of the companies in the same industry are more expensive than ARGX, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.93, ARGX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.08 | ||
| Fwd PE | 26.92 |
4.2 Price Multiples
89.81% of the companies in the same industry are more expensive than ARGX, based on the Enterprise Value to EBITDA ratio.
90.75% of the companies in the same industry are more expensive than ARGX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 168.71 | ||
| EV/EBITDA | 95.6 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 177.32% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y310.28%
EPS Next 3Y177.32%
5. Dividend
5.1 Amount
ARGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
845.95
-6.09 (-0.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners43%
Inst Owner Change2.31%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap52.08B
Revenue(TTM)3.60B
Net Income(TTM)1.28B
Analysts83.2
Price Target978.22 (15.64%)
Short Float %3.02%
Short Ratio5.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14.45%
Revenue beat(16)13
Avg Revenue beat(16)17.87%
PT rev (1m)13.23%
PT rev (3m)14.07%
EPS NQ rev (1m)0.26%
EPS NQ rev (3m)-1.69%
EPS NY rev (1m)7.5%
EPS NY rev (3m)22.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.19%
Revenue NY rev (1m)2.85%
Revenue NY rev (3m)6.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.08 | ||
| Fwd PE | 26.92 | ||
| P/S | 17.07 | ||
| P/FCF | 168.71 | ||
| P/OCF | 129 | ||
| P/B | 8.54 | ||
| P/tB | 8.86 | ||
| EV/EBITDA | 95.6 |
EPS(TTM)13.41
EY1.59%
EPS(NY)31.43
Fwd EY3.71%
FCF(TTM)5.01
FCFY0.59%
OCF(TTM)6.56
OCFY0.78%
SpS49.55
BVpS99.01
TBVpS95.45
PEG (NY)0.07
PEG (5Y)N/A
Graham Number172.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 6.01% | ||
| ROICexc | 16.72% | ||
| ROICexgc | 18.56% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 30.57 |
F-Score6
WACC7.43%
ROIC/WACC0.81
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
EPS Next Y939.88%
EPS Next 2Y310.28%
EPS Next 3Y177.32%
EPS Next 5Y107.34%
Revenue 1Y (TTM)64.71%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
Revenue Next Year94.97%
Revenue Next 2Y63.05%
Revenue Next 3Y48.34%
Revenue Next 5Y34.98%
EBIT growth 1Y208.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1535.54%
EBIT Next 3Y218.56%
EBIT Next 5Y122.64%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.76%
OCF growth 3YN/A
OCF growth 5YN/A
ARGENX SE - ADR / ARGX FAQ
What is the fundamental rating for ARGX stock?
ChartMill assigns a fundamental rating of 6 / 10 to ARGX.
What is the valuation status of ARGENX SE - ADR (ARGX) stock?
ChartMill assigns a valuation rating of 6 / 10 to ARGENX SE - ADR (ARGX). This can be considered as Fairly Valued.
Can you provide the profitability details for ARGENX SE - ADR?
ARGENX SE - ADR (ARGX) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for ARGX stock?
The Earnings per Share (EPS) of ARGENX SE - ADR (ARGX) is expected to grow by 939.88% in the next year.